Physician profile
Adam C Stein
NPI 1962667956
$437,719.02
in general payments reported to CMS, 2019-2025
14 companies · $65K in 2025
The $65K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $51K · 2021: $20K · 2022: $124K · 2023: $25K · 2024: $68K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $134K · Consulting Fee: $11K · Travel and Lodging: $9,678 · Food and Beverage: $2,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $134,142.76 |
| Consulting Fee | $11,053.00 |
| Travel and Lodging | $9,678.09 |
| Food and Beverage | $2,723.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $183,536.06 | 2019-2025 | Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $178,466.75 | 2019-2025 | Entyvio |
| Pfizer INC. | $56,661.10 | 2019-2025 | |
| Amgen INC. | $7,521.74 | 2024 | Procysbi |
| Horizon Therapeutics Plc | $6,760.08 | 2022 | |
| Ironwood Pharmaceuticals, INC | $3,719.00 | 2024 | |
| Alcresta Therapeutics, INC. | $500.00 | 2019 | |
| Gi Supply, INC. | $250.00 | 2019 | |
| Boston Scientific Corporation | $124.97 | 2021 | |
| Celgene Corporation | $116.95 | 2021 | |
| Genzyme Corporation | $36.38 | 2025 | |
| Covidien LP | $25.99 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.